Inhibidores de la aromatasa para el tratamiento del cáncer de mama avanzado en mujeres posmenopáusicas
Información
- DOI:
- https://doi.org/10.1002/14651858.CD003370.pub3Copiar DOI
- Base de datos:
-
- Cochrane Database of Systematic Reviews
- Versión publicada:
-
- 07 octubre 2009see what's new
- Tipo:
-
- Intervention
- Etapa:
-
- Review
- Grupo Editorial Cochrane:
-
Grupo Cochrane de Cáncer de mama
- Copyright:
-
- Copyright © 2009 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Cifras del artículo
Altmetric:
Citado por:
Autores
Contributions of authors
Judith Bliss wrote the original protocol, initiated the review with Lorna Gibson and reviewed the review.
Lorna Gibson worked with the Cochrane Breast Group to identify the initial list of references; she then worked through the list to identify eligible trials. Lorna carried out the first independent data extraction from the eligible trials and was a main contributor to the review and analysis, and the update.
Claire Dawson carried out a second independent extraction of data from the eligible trials and contributed to the original review.
David Lawrence carried out an independent check of the data extraction for accuracy and consistency and was a main contributor to the original review analysis, and the update.
Sources of support
Internal sources
-
Cancer Research UK, UK
External sources
-
No sources of support supplied
Declarations of interest
One of the authors (JMB) is a member of the management group and grant holder for the Intergroup Exemestane Study. This is funded by Pfizer, the producers of the aromatase inhibitor exemestane.
Acknowledgements
The authors were funded by Cancer Research UK. Lorna Gibson would like to thank Julian Peto and Isabel dos Santos Silva for their support. The authors would like to thank the Cochrane Breast Cancer Group for their support and are indebted to Olivia Fletcher for critical reading of the manuscript.
Version history
| Published | Title | Stage | Authors | Version |
| 2009 Oct 07 | Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women | Review | Lorna Gibson, David Lawrence, Claire Dawson, Judith Bliss | |
| 2009 Jul 08 | Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women | Review | Lorna Gibson, Claire Dawson, David Lawrence, Judith Bliss | |
| 2001 Oct 23 | Aromatase Inhibitors for treatment of metastatic breast cancer | Protocol | Judith Bliss, Lorna Gibson | |
Differences between protocol and review
Many of the data required to carry out analyses of prospectively identified subgroups, as set out in the review protocol, were not available. We could not, therefore, identify specific subgroups of women who may benefit from AI use.
Notes
This updated review includes the following additional seven trials to the 30 in the original publication: Chia 2008; Gale 1994; Garcia‐Giralt 1992; Goss 2007; Lundgren 1989; Samonis 1994. There were also two papers by Mourisden and colleagues (Mourisden 2004; Mourisden 2007) which contributed follow‐up information.
The update demonstrated a survival benefit of 10% with the use of AIs for the treatment of advanced (metastatic) breast cancer, compared to 11% in the original review.
